{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:16:09Z","timestamp":1716855369968},"reference-count":36,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.vaccine.2024.04.058","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T19:46:56Z","timestamp":1714765616000},"page":"3522-3528","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunogenicity and safety of a recombinant Omicron BA.4\/5-Delta COVID-19 vaccine ZF2202-A in Chinese adults"],"prefix":"10.1016","volume":"42","author":[{"given":"Hua","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangli","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihui","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaqin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maodi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianqian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.04.058_b0005","unstructured":"Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. https:\/\/www.who.int\/news\/item\/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern."},{"key":"10.1016\/j.vaccine.2024.04.058_b0010","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41586-022-04980-y","article-title":"BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection","volume":"608","author":"Cao","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2024.04.058_b0015","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S1473-3099(22)00422-4","article-title":"Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5","volume":"22","author":"Arora","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.04.058_b0020","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijid.2023.01.024","article-title":"Emergence and geographic dominance of Omicron subvariants XBB\/XBB.1.5 and BF.7 - the public health challenges","volume":"128","author":"Velavan","year":"2023","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.04.058_b0025","doi-asserted-by":"crossref","unstructured":"Ren W, Zhang Y, Rao J, Wang Z, Lan J, Liu K, et al. Evolution of immune evasion and host range expansion by the SARS-CoV-2 B. 1.1. 529 (Omicron) variant. MBio. 2023;14:e00416-23.","DOI":"10.1128\/mbio.00416-23"},{"key":"10.1016\/j.vaccine.2024.04.058_b0030","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41586-021-04389-z","article-title":"Considerable escape of SARS-CoV-2 Omicron to antibody neutralization","volume":"602","author":"Planas","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2024.04.058_b0035","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41591-022-01705-6","article-title":"Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination","volume":"28","author":"Perez-Then","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2024.04.058_b0040","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1038\/s41467-022-30884-6","article-title":"Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine","volume":"13","author":"Patalon","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2024.04.058_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2022.12.003","article-title":"Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C in adults previously vaccinated with inactivated vaccine: A randomized, double-blind, placebo-controlled phase 1\/2 clinical trial","author":"Hannawi","year":"2023","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2024.04.058_b0050","unstructured":"Statement on the antigen composition of COVID-19 vaccines.https:\/\/www.who.int\/news\/item\/18-05-2023-statement-on-the-antigen-composition-of-covid-19-vaccines."},{"key":"10.1016\/j.vaccine.2024.04.058_b0055","unstructured":"Statement on the antigen composition of COVID-19 vaccines.https:\/\/www.who.int\/news\/item\/13-12-2023-statement-on-the-antigen-composition-of-covid-19-vaccines."},{"key":"10.1016\/j.vaccine.2024.04.058_b0060","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa2208343","article-title":"A bivalent Omicron-containing booster vaccine against Covid-19","volume":"387","author":"Chalkias","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.04.058_b0065","first-page":"12","article-title":"The bivalent COVID-19 booster immunization after three doses of inactivated vaccine augments the neutralizing antibody response against circulating Omicron sublineages","author":"He","year":"2022","journal-title":"J Clin Med"},{"issue":"722\u201333","key":"10.1016\/j.vaccine.2024.04.058_b0070","first-page":"e11","article-title":"A universal design of Betacoronavirus vaccines against COVID-19, MERS, and SARS","volume":"182","author":"Dai","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2024.04.058_b0075","unstructured":"COVID-19 vaccine tracker. Approved vaccines(https:\/\/covid19.trackvaccines.org\/vaccines\/approved\/)."},{"key":"10.1016\/j.vaccine.2024.04.058_b0080","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa2202261","article-title":"Efficacy and safety of the RBD-dimer-based Covid-19 vaccine ZF2001 in adults","volume":"386","author":"Dai","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.04.058_b0085","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S1473-3099(21)00127-4","article-title":"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: Two randomised, double-blind, placebo-controlled, phase 1 and 2 trials","volume":"21","author":"Yang","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.04.058_b0090","doi-asserted-by":"crossref","first-page":"e2179357","DOI":"10.1080\/22221751.2023.2179357","article-title":"A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1\/BA.2\/BA.2.12.1\/BA.4\/BA.5","volume":"12","author":"Duan","year":"2023","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.vaccine.2024.04.058_b0095","doi-asserted-by":"crossref","first-page":"e07388","DOI":"10.1016\/j.heliyon.2021.e07388","article-title":"Impact of online education on fear of academic delay and psychological distress among university students following one year of COVID-19 outbreak in Bangladesh","volume":"7","author":"Hossain","year":"2021","journal-title":"Heliyon"},{"key":"10.1016\/j.vaccine.2024.04.058_b0100","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jiph.2021.04.005","article-title":"SARS-CoV-2 infection during pregnancy and pregnancy-related conditions: Concerns, challenges, management and mitigation strategies-a narrative review","volume":"14","author":"Kumar","year":"2021","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.vaccine.2024.04.058_b0105","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/s41591-022-02051-3","article-title":"Acute and postacute sequelae associated with SARS-CoV-2 reinfection","volume":"28","author":"Bowe","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2024.04.058_b0110","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1080\/21645515.2020.1830683","article-title":"SARS-CoV-2 reinfection and implications for vaccine development","volume":"16","author":"Nainu","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2024.04.058_b0115","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.1080\/21645515.2021.1963601","article-title":"Impact of SARS-CoV-2 delta variant (B. 1.617. 2) in surging second wave of COVID-19 and efficacy of vaccines in tackling the ongoing pandemic","volume":"17","author":"Tareq","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2024.04.058_b0120","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1056\/NEJMc2202092","article-title":"Duration of shedding of culturable virus in SARS-CoV-2 Omicron (BA.1) infection","volume":"387","author":"Boucau","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.04.058_b0125","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1007\/s12325-022-02206-1","article-title":"Immune persistence and safety after SARS-CoV-2 BNT162b1 mRNA vaccination in Chinese adults: A randomized, placebo-controlled, double-blind phase 1 trial","volume":"39","author":"Li","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.vaccine.2024.04.058_b0130","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1473-3099(21)00681-2","article-title":"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials","volume":"22","author":"Zeng","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.04.058_b0135","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1007\/s11427-022-2207-7","article-title":"A spike-trimer protein-based tetravalent COVID-19 vaccine elicits enhanced breadth of neutralization against SARS-CoV-2 Omicron subvariants and other variants","volume":"66","author":"Wang","year":"2023","journal-title":"Sci China Life Sci"},{"issue":"25\u201334","key":"10.1016\/j.vaccine.2024.04.058_b0140","first-page":"e5","article-title":"Enhanced neutralization of SARS-CoV-2 variant BA.2.86 and XBB sub-lineages by a tetravalent COVID-19 vaccine booster","volume":"32","author":"Wang","year":"2024","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2024.04.058_b0145","first-page":"10","article-title":"Immunogenicity evaluating of the multivalent COVID-19 inactivated vaccine against the SARS-CoV-2 variants","author":"Zhang","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2024.04.058_b0150","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1038\/s41591-022-02031-7","article-title":"Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: A phase 2\/3 trial","volume":"28","author":"Chalkias","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2024.04.058_b0155","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S2352-4642(22)00376-5","volume":"7","author":"Gao","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.vaccine.2024.04.058_b0160","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1038\/s41467-023-39766-x","article-title":"Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men","volume":"14","author":"Hannawi","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2024.04.058_b0165","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26082210","article-title":"Efficacy of phytochemicals derived from Avicennia officinalis for the management of COVID-19: A combined in silico and biochemical study","volume":"26","author":"Mahmud","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.vaccine.2024.04.058_b0170","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/biology10010002","article-title":"Drug repurposing approach against novel coronavirus disease (COVID-19) through virtual screening targeting SARS-CoV-2 main protease","volume":"10","author":"Chowdhury","year":"2020","journal-title":"Biology"},{"key":"10.1016\/j.vaccine.2024.04.058_b0175","unstructured":"World Health Organization. Report of the meeting of the WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) held on 16-17 March 2023. https:\/\/www.who.int\/news\/item\/14-04-2023-report-of-the-meeting-of-the-who-technical-advisory-group-on-covid-19-vaccine-composition-(tag-co-vac)-held-on-16-17-march-2023;14 April 2023."},{"key":"10.1016\/j.vaccine.2024.04.058_b0180","unstructured":"World Health Organization. Coronavirus disease (COVID-19) Epidemiological Updates and Monthly Operational Updates.https:\/\/www.who.int\/publications\/m\/item\/covid-19-epidemiological-update-15-march-2024; 15 March 2024."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2400495X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2400495X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T20:56:38Z","timestamp":1716843398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2400495X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":36,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0264410X2400495X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.04.058","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of a recombinant Omicron BA.4\/5-Delta COVID-19 vaccine ZF2202-A in Chinese adults","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.04.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}